What is partial response vs complete response in HER2-Positive Breast Cancer treatment

Understanding Partial Response vs Complete Response in HER2-Positive Breast Cancer

Great question—these terms are central to how doctors evaluate whether your treatment is working. Let me break down what they mean and why they matter for your care.

Complete Response (CR)

A complete response means that imaging tests (like CT scans, MRI, or PET scans) can no longer detect any visible cancer. The tumor has either disappeared entirely or shrunk to a point where it's no longer measurable on standard imaging.

What this means clinically:

• No evidence of the original tumor
• No new tumors have appeared
• Tumor markers (blood tests that track cancer activity) have normalized or significantly decreased
• This is the goal doctors aim for with treatment

Partial Response (PR)

A partial response means the cancer has shrunk by a measurable amount—typically at least 30% reduction in tumor size—but some cancer is still visible on imaging. The tumor hasn't disappeared, but it's getting smaller.

What this means clinically:

• Visible tumor remains but is responding to treatment
• The cancer is not progressing (getting worse)
• Treatment is working, but not completely eliminating the disease
• Further treatment decisions depend on how well the tumor continues to respond

Why This Matters for HER2-Positive Breast Cancer

According to NCCN Guidelines for Invasive Breast Cancer, treatment decisions for HER2-positive disease depend heavily on your response to therapy:

If you achieve complete response after preoperative (before surgery) treatment:

• You'll typically complete up to 1 year of HER2-targeted therapy with trastuzumab (Herceptin) alone or combined with pertuzumab (Perjeta)
• This extended therapy helps prevent recurrence

If you have residual disease (meaning some cancer remains after preoperative treatment):

• Your doctor may switch to ado-trastuzumab emtansine (Kadcyla), which is an antibody-drug conjugate—a targeted therapy that delivers chemotherapy directly to HER2-positive cancer cells
• If Kadcyla causes side effects, you may continue with trastuzumab and/or pertuzumab to complete 1 year of HER2-targeted therapy

How Response is Measured

Your medical team uses standardized criteria called RECIST (Response Evaluation Criteria in Solid Tumors) to measure response:

• Complete Response (CR): All tumors disappear
• Partial Response (PR): Tumor shrinks by at least 30%
• Stable Disease (SD): Tumor size stays relatively the same
• Progressive Disease (PD): Tumor grows by 25% or more

Important Questions to Ask Your Oncologist

1. What imaging tests will be used to measure my response, and how often?
2. What counts as a good response for my specific situation?
3. If I achieve partial response, what's the plan for next treatment?
4. How will we know if treatment is working between imaging scans? (tumor markers, symptoms, etc.)
5. What happens if I don't achieve the response we're hoping for?

The Bottom Line

Both partial and complete responses indicate that treatment is working—the difference is in degree. Complete response is ideal, but partial response can still represent meaningful progress. Your oncologist will use your response pattern, along with other factors like your overall health and side effects, to decide whether to continue, modify, or change your treatment plan.

According to NCCN Guidelines, the key is that your care team monitors your response carefully and adjusts your treatment strategy based on how your individual cancer responds to therapy.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.